Agilent Technologies (NYSE:A) Position Boosted by Verition Fund Management LLC

Verition Fund Management LLC increased its position in shares of Agilent Technologies (NYSE:A) by 37.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,661 shares of the medical research company’s stock after acquiring an additional 6,488 shares during the period. Verition Fund Management LLC’s holdings in Agilent Technologies were worth $1,585,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Agilent Technologies by 8.1% in the 4th quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock valued at $1,718,808,000 after acquiring an additional 1,912,186 shares during the last quarter. Renaissance Technologies LLC grew its stake in Agilent Technologies by 325.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after buying an additional 1,812,500 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Agilent Technologies by 145.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after buying an additional 1,023,099 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in Agilent Technologies during the 3rd quarter worth approximately $58,550,000. Finally, Bank of Montreal Can grew its stake in Agilent Technologies by 187.3% during the 4th quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after buying an additional 483,721 shares during the last quarter.

How to Become a New Pot Stock Millionaire

A number of research firms have weighed in on A. Robert W. Baird reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agilent Technologies in a research report on Thursday, January 18th. JPMorgan Chase raised their price target on Agilent Technologies from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Tuesday, March 13th. Barclays reissued a “buy” rating and issued a $74.00 price target on shares of Agilent Technologies in a report on Monday, January 8th. Finally, ValuEngine cut Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $72.48.

In related news, insider Patrick Kaltenbach sold 4,000 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $67.28, for a total value of $269,120.00. Following the completion of the sale, the insider now directly owns 72,547 shares of the company’s stock, valued at $4,880,962.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $72.50, for a total value of $1,584,125.00. Following the completion of the sale, the chief executive officer now directly owns 324,687 shares of the company’s stock, valued at $23,539,807.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 66,400 shares of company stock worth $4,809,327.

Agilent Technologies stock traded down $2.03 during midday trading on Friday, reaching $63.65. The stock had a trading volume of 3,578,587 shares, compared to its average volume of 2,321,138. The stock has a market capitalization of $21,180.22, a P/E ratio of 26.97, a PEG ratio of 2.18 and a beta of 1.31. Agilent Technologies has a twelve month low of $52.31 and a twelve month high of $75.00. The company has a current ratio of 3.23, a quick ratio of 2.78 and a debt-to-equity ratio of 0.40.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.08. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Agilent Technologies had a return on equity of 17.70% and a net margin of 4.25%. During the same quarter in the previous year, the firm posted $0.53 earnings per share. sell-side analysts predict that Agilent Technologies will post 2.7 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 25th. Investors of record on Tuesday, April 3rd will be paid a $0.149 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend is Monday, April 2nd. Agilent Technologies’s dividend payout ratio (DPR) is 25.42%.

ILLEGAL ACTIVITY WARNING: “Agilent Technologies (NYSE:A) Position Boosted by Verition Fund Management LLC” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/verition-fund-management-llc-increases-holdings-in-agilent-technologies-inc-a.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply